Share Name Share Symbol Market Type Share ISIN Share Description
Scancell Hldgs LSE:SCLP London Ordinary Share GB00B63D3314 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.35p +3.04% 11.85p 54,815 16:16:45
Bid Price Offer Price High Price Low Price Open Price
11.50p 12.20p 12.00p 11.50p 11.50p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -4.50 -1.36 46.0

Scancell Hldgs (SCLP) Latest News

More Scancell Hldgs News
Scancell Hldgs Takeover Rumours

Scancell Hldgs (SCLP) Share Charts

1 Year Scancell Hldgs Chart

1 Year Scancell Hldgs Chart

1 Month Scancell Hldgs Chart

1 Month Scancell Hldgs Chart

Intraday Scancell Hldgs Chart

Intraday Scancell Hldgs Chart

Scancell Hldgs (SCLP) Discussions and Chat

Scancell Hldgs Forums and Chat

Date Time Title Posts
19/8/201809:43Using immunology to fight cancer.17,051
09/7/201812:26Could this be the end of cancer?761
20/5/201817:25Scancell short thread2
22/8/201608:20Question11
16/8/201408:47Using immunology to fight cancer (LTH W/O Rose Tints - Free Speech Thread)161

Add a New Thread

Scancell Hldgs (SCLP) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Scancell Hldgs trades in real-time

Scancell Hldgs (SCLP) Top Chat Posts

DateSubject
19/8/2018
09:20
Scancell Hldgs Daily Update: Scancell Hldgs is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SCLP. The last closing price for Scancell Hldgs was 11.50p.
Scancell Hldgs has a 4 week average price of 11p and a 12 week average price of 11p.
The 1 year high share price is 19.25p while the 1 year low share price is currently 9.50p.
There are currently 387,796,556 shares in issue and the average daily traded volume is 238,443 shares. The market capitalisation of Scancell Hldgs is £45,953,891.89.
09/8/2018
13:22
j777j: Scancell Holdings part of the new cancer revolutionShare 12:48 09 Aug 2018The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncologyINVESTMENTOVERVIEW: SCLPTHE BIGPICTUREThe company's innovations have shown some early promise - particularly SCIB-1, which has been used with some success to treat melanomaThe fight against cancer has moved into a new phase as drugs are developed that use the body's immune system to tackle the killer disease.And AIM-listed Scancell Holdings (LON:SCLP) is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing early promise.In May investors got behind the business, backing a placing and open offer of new shares that brought in £8.7mln before expenses.Bankrolling development That cash will fund early clinical trials of a drug generated using its Moditope platform as well as supporting the development of its more advanced assets.They are SCIB-1 and SCIB-2, which target and stimulate existing cells that make up the body's defence mechanisms.At the turn of the year, Scancell reported the "compelling" results of a phase I/II trial of SCIB-1, and the immunotherapy has continued to impress since.Meanwhile, last December Cancer Research UK agreed to fund and sponsor a phase I/II lung cancer clinical study of its SCIB-2 vaccine in combination with another type of drug called a checkpoint inhibitor.Lung cancer is a killerLung cancer remains one of the most difficult cancers to treat and accounts for more than a quarter of all cancer deaths.That's more than breast, prostate and colon cancers combined. Around 228,000 people receive a lung cancer diagnosis in the US alone and more than 160,000 will not survive.A read-out from the study is expected in the first half of next year.ImmunoBody and Moditope Both SCIB-1 and SCIB-2 emerged from Scancell's ImmunoBody platform.MODI-1 is its first drug using the company's Moditope technology. Initially, it will be deployed in the clinic to treat breast and ovarian cancers as well as sarcoma (tumours found in fat, muscle, bone and tendons).MODI-1 acts to stimulate the production of killer CD4+ T cells that seek out and kill tumour cells that would otherwise be hidden from the immune system.  Partnership renewedScientists at the Karolinska Institute, led by Professors Lars Klareskog and Vivianne Malmström, uncovered an essential role for citrullinated proteins, which are normally associated with arthritis, in this process.On Thursday (Aug 9), the company extended its collaboration with the rheumatology of the Swedish medical research university.The share price, which has fluctuated between 10-16p in the past year, appears to have found a level recently around 12p.At that price, the company is worth just under £44mln. Whether this is a fair valuation of the business is open to interpretation.Hard to valueNormally, you would carry out discounted cash flow analysis to assess just what Scancell's assets are worth.But as Hardman, the City research house pointed out in a recent note, the company's innovations are too early stage to be subjected to this sort of analysis.Instead, it's probably worth looking at the trends within the industry and the deals being done.Last year there were 35 transactions in the oncology sector in excess of US$1bn, according to EvalutePharma,Of that total, 32 were focused on immuno-oncology. In other words, this is a particularly active (and potentially rewarding) area of R&D.As Hardman analyst Martin Hall said in his note: "Scancell's proprietary technologies are in the 'hot' area of immuno-oncology and targeting markets of significant unmet medical need."Recent deals have demonstrated the price that big pharma is willing to pay for validated assets in the field."
20/6/2018
11:46
panama7: Chelsea, you should have learnt after all this time the BOD couldn't care less about their PI's and care even less about the share price. It suits the BOD to have a low share price as was shown with the change of options targets and Chiplin helping himself to 2m shares at an average of 11p when both fund raisings were oversubscribed.
30/5/2018
08:01
tosh123: Torquay, none of the above justifies the 100% failure to deliver anything on time, and indeed even more significantly, failure to deliver many things at all. There have been numerous occasions where we have been told that its a " pivotal year " and that deals will be done, yet here we are some 6 - 7 years later, with a distressed share price, numerous dilutions, and potentially still looking at another 18 months to 2 years, before we may see any major shift in the share price. Whilst i appreciate the world of baby bio's is always evolving, this is Scancells core business, and as such, they should know their market. Delays are inevitable especially when you're talking about in depth trials, however, just for once it would be nice to see a realistic time frame announced, followed by an EARLY , or at least, on time, delivery. That said, as you rightly point out, the big buy back on all of the above, is the retention of all the IP, however, that IP is only really worth substantial money once the concepts behind the IP have been proven and verified, which we are still some way off, hence the 18 month - 2 years, before IMHO , we see any share price movement ABOVE the existing highs of a few years ago. Managed badly ???? Yes i think so, very badly. But im still here, and so are many other LTH's, so we all have faith, even if that faith is of varying magnitudes.
30/5/2018
07:30
torquayfan: P7. Developing pre-clinical science and initiating clinical trials is a little different from say, building a house or making widgets - Scancell as a Biotech are surely not alone in setting targets which are then hard to attain. I daresay that BoD have met a few timescales but you go trawling for them if you have time. I mentioned the problem of ''managing a bundle of ever expanding and increasingly patented science with a tiny Team'' and I think it a fair point, particularly given the depth and range of Scancell's science portfolio! If all Scancell had now was SCIB1 for example - I'm guessing we'd be further along but that'd be on a much smaller path ? As for BoD supporting the share price - their main business is to take the science through the 'maze' to commercialisation in some way - it's not proving easy with limited resources but Scancell ARE getting there. Just look what's on board now ! Of course, BoD HAVE tried in many ways to support the share price - but this is Biotech UK and this it is the way it is. Hard going. But at least the IP has so far been retained. What Scancell have put together is a truly amazing achievement and well done the BoD - the share price will zoom in due course. Of that I am certain. ATB
24/5/2018
09:57
panama7: RH, the share price is consolidating at 14p, the share price was 34p when Goodfellow released his video, the BOD should have been ethically and morally obligated to keep the share price above that price. they have left those unfortunate Investors out of pocket for 5 years and counting and have shown by their words , actions and deeds they couldn't care less about their PI's.
22/5/2018
12:54
gazza: Is selling a good thing? Inan, Try, if you can, to get your head round it, I will try and make it simple for you: When I did economics in nursery skool many years ago, we learned the funamental principle of price is determined by supply and demand. Plentiful supply and low demand would cause the price to fall. On the other hand, limited supply and high demand would cause the price to rise. Now here's the thing: What would happen if there was NO supply (ie, no sellers)? There would be no price, no trades happening that would cause the price to move either UP or DOWN. In the case of a share, if noone sold, noone could buy either and the share price would stagnate. This is what is meant by LIQUIDITY, it is not what happens in your head or should I say thou head? What WE need, as shareholders in SCLP is plenty of eager buyers whose apetite for shares is met by some sellers. In this scenario, the price may even go up.
06/3/2018
15:01
tosh 123: Ineptico.... I stand by both of those posts... I'm really not sure what point you're trying to prove... are you going mad or something ? Scancell is all about potential, otherwise there would be no need for any further trials, or any further funding, as we would be generating revenue and paying a dividend ! Which bit of that most basic of business principle don't you get ? The market ( which is currently what determines the share price ) is well aware of THE RISKS ( as are the BOD ) hence the share price is where its at.. simple ! It is all about risk vs reward, as it is with EVERY investment... and the BOD are , by their own admission, trying to reduce the risk, and thereby, encourage an increase in the share price... Contrary to your now " proven to be totally wrong " posts that there is no risk.
23/1/2018
21:30
tosh123: And with that one post you merely reiterate your complete and utter lack of any understanding what so ever.... You Buffoon ! Firstly Phase III trials, have not only been financed, but they have been completed... Sentiment ? I think not, its down to the FACT that IMM have done exactly what they promised they would do, and completed Phase III. Secondly, as well as completing Phase III trials ( which could not have had any major side effects otherwise the trial would have been stopped ), They have also announced that the recipients of the drug, and indeed the trial coordinators, have asked to EXTEND the treatment for another 6 months.... Sentiment ? I think not, its down to the fact that the trial has apparently been a success. The fact that over the last few years, IMM has gradually mitigated risk is exactly why the share price has risen nearly 400%, not sentiment.... Sentiment is driven by risk, the more comfortable people are that their risks are being reduced, the more the share price increases, the two are directly proportional. rHatton... Unfortunately i think you're right. I would venture that any funding will now be south of the current SP, which is clearly a real kick in the teeth for existing shareholders, especially those who continue to try and support the current levels, by buying more. There is now a real risk that shareholders will be diluted out of existence. Clearly, what we all hope for is someone with deep pockets and credibility to ride over the hillside and provide full financial support, for the next 3 years, however, bearing in mind that the " data room " has been seen by numerous candidates for funding, i think this scenario is becoming more and more unlikely. As i have said before, i will continue to hold " just in case " as if this does make it through the next few years, the potential remains meteoric, but lets not kid ourselves, this is now a longer term investment than it was perceived to be many years ago. I agree that the IP has somewhat increased with the evolution of Modi, but that has not, nor will it, be reflected in the share price until the OBVIOUS RISKS have been mitigated. All the while we have idiots ramping £6 / share, and claiming zero risk etc, he will be the laughing stock of the BB.
30/12/2017
14:46
drdobson1: ONW-Personally thought what a great post. I have been thinking along same lines re Inanaco.Is he a lot cleverer than I have given him credit for. Create the impression of being a long term holder but all the time is he has been trading SCLP-probably only revealed when his ego could not cope with the beating it was taking from the declining share price and he thought I have to be seen as a much better investor/trader than the ASTUTE. On the VAL board he was called a shorter and that he and C7 were part of a boiler room crew.Well I thought that a load of nonsense but perhaps he is a secret trader as you say that stock is a lot more volatile than here. Good traders are often perceived as being devious and only out for themselves and he certainly fits that bill By portraying himself as a self taught science guru he has sought to distract from his game plan which is to destroy investor sentiment and cause maximum bulletin board disharmony. He probably wants to get the SCLP share price to fall so he can buy and trade in fact he may not have much of a holding at all. He is as cunning as a cartload of monkeys and slippery as an eel and has me totally fooled or am I being too kind t9 him. Anyway all have a happy new year
23/11/2017
16:00
inanaco: ""if you make a statement that i cannot reason against then your statement becomes the lead policy which i then support "" yes because most of the intense discussion are on the science that impact IP value """There are plenty. Here's just one: share price down from 60p to 12p. Isn't that a negative? I make it negative 48p."""" That's sentiment has the science stood still in all that time, ? ""the Shareprice is not relevant as all i am trying to show is it's cheap relative to the IP.<<br /> Two fatal flaws in one sentence: 1) How on earth can you say the share price isn't relevant??!! It is very relevant if you have invested and need to sell.""" You have now added a third party ie somebody that needs to sell, that is not my position. """It is relevant to how easy it is for SCLP to raise new funds and at what price those funds are raised and therefore relevant to the amount of dilution of our investment.""" Very true, But like you have done, you can then look at the shares in issue and assess the likely outcome of capital growth based on the resultant influx of cash and how the science develops from that Dilution so has a result on both sides of the equation Ie A bigger increase in capital growth than was forecast without that expenditure. """ all i am trying to show is it's cheap relative to the IP.<<br /> Well you haven't! """ I have but maybe you have not understood the years of comparing and understanding of the science of others with wildforce allowed us to pretty well place Scancell into the market place and place reasoned value to the IP """" lozan/Tosh, Mr W cannot explain why the IP has a lower value to the share price <<br /> The IP has a lower value to the SP? Are you saying the IP is not worth 12p? """ actually the buying of the share by Loz at 47p and selling at 53p would indicate Loz buying at the level was cheap and selling at 53p produced a true value event. to then argue its only worth 12p with that evidence would be difficult ... but Loz would have to show comparative value to the IP .. being 12p .. which i suspect would be impossible """not a point worth discussing as No conclusion will be ever drawn from it as its not linked to IP only market sentiment on any particular day ...<<br /> You have a point, why worry about a share price of 12.3 when it could easily be 12.5 tomorrow."" I am not worried about the share price, i already feel the value way exceeds this level, and indeed the Board of Scancell accept that, hence they want to raise the big amounts not based on share price but IP .. however they will always have the fall back position of market priced cash raising which again is Not Ip priced cash raising like a deal """thus all the posts can be dismissed as not relevant, <<br /> In YOUR opinion, which here does not command a very high level of respect"""" then show me posts that you feel are of High Value that i have missed, like i said I debate for my own investment position ..I defend Scancell because I am invested not because your invested,
Scancell Hldgs share price data is direct from the London Stock Exchange
add chat code
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20180819 11:29:41